The Gummy Project

In Preparation for Launch of the Gummy Project, Potent Ventures Activates Partnership with OCEARCH Through a Matching Gift Campaign Designed to Inspire the Global Community

Potent Ventures Inc. (CSE: POT) (FSE: 0OS) (OTCQB: POTVF) ("Potent" or the "Company") is excited to announce that the Company has activated its previously announced partnership with OCEARCH, a global non-profit organization conducting uprecedented research on shark populations in order to accelerate the ocean's return to balance and abundance.

In an effort to inspire communities to think globally and act locally when it comes to conservation, The Gummy Project is playing a key role in supporting OCEARCH's current collaborative study focused on the North Atlantic White Shark. To date, the study is over 80% complete, with Expedition Carolinas focused on the final piece of the puzzle, determining where these white sharks mate. The Gummy Project is pleased to donate $15,000 USD through a matching gift campaign. Kicking off March 22nd, 2022, OCEARCH supporters will be invited to support Expedition Carolinas in a unique way by supporting research in real-time.

"We are thrilled to put our partnership with OCEARCH into action and seize this opportunity to inspire a global network to participate in Expedition Carolinas through a unique giving campaign," said Mr. Charlie Lamb, CEO of The Gummy Project. "This is a strong first step for our Partnership with OCEARCH which we hope will inspire others to contribute to the Expedition Carolinas and OCEARCH."

"Everything that OCEARCH does is made possible through the support of our community. Their generosity allows us to educate thousands of students annually, advances cutting-edge research, and ultimately helps us restore balance and abundance to our oceans. We are very grateful to The Gummy Project for supporting our mission in a way that encourages others to deepen their support." - Stephanie K. Brown, Development Director.

About Expedition Carolinas

The OCEARCH Global Tracker led the team to the waters off the Carolina region where a dynamic confluence of currents and water temperature produces high productivity and potential food sources for sharks. OCEARCH's tracking data led them to the area off Cape Hatteras (where the "faunal break" divides the northern Atlantic coast and the southern Atlantic coast of the U.S.) where they watch the big males and females come together for a few weeks there before a number of the adult females head offshore on their migratory loops in the open Atlantic, where OCEARCH thinks they are gestating their developing young.

About OCEARCH

OCEARCH is a global non-profit organization conducting unprecedented research on our ocean's giants in order to help scientists collect previously unattainable data in the ocean. Our mission is to accelerate the ocean's return to balance and abundance through fearless innovations in critical scientific research, education, outreach, and policy using unique collaborations of individuals and organizations in the U.S and abroad. OCEARCH is recognized as a world leader in generating scientific data related to tracking (telemetry), and biological studies of keystone marine species such as great white sharks, tiger sharks, and more. OCEARCH provides a free open-sourced Shark Tracking service and app that allows scientists, educators, and fans alike to learn about the never before documented movements of our ocean's animals. OCEARCH has embarked on 40 research expeditions. Learn more at OCEARCH.ORG.

About Potent Ventures

We are a growing community of individuals and organizations who believe small contributions can add up to something big. We sell low sugar, plant based gummy products while raising money (and awareness) to support endangered keystone species. We are the only "better for you" candy company that is built to support our planet's most precious species and ecosystems, while educating our future generations on the steps we must take today, to ensure a viable tomorrow.

Charlie Lamb, President & CEO, Director
Telephone: 1(236) 317-2812 - Toll free 1(888) 556-9656
E-mail: investors@potent-ventures.com
www.shopgummies.com

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward Looking Statements

Certain information set forth in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties. All statements other than statements of historical fact are forward-looking statements, including, without limitation, statements regarding future financial position, business strategy, use of proceeds, corporate vision, proposed acquisitions, partnerships, joint-ventures and strategic alliances and co-operations, budgets, cost and plans and objectives of or involving the Company. Such forward-looking information reflects management's current beliefs and is based on information currently available to management. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "forecasts", "predicts", "intends", "targets", "aims", "anticipates", "may" or "believes" or variations (including negative variations) of such words and phrases or may be identified by statements to the effect that certain actions "may", "could", "should", "would", "might" or "will" be taken, occur or be achieved. A number of known and unknown risks, uncertainties and other factors may cause the actual results or performance to materially differ from any future results or performance expressed or implied by the forward-looking information. These forward-looking statements are subject to numerous risks and uncertainties, certain of which are beyond the control of the Company including, but not limited to, the impact of general economic conditions, industry conditions, risks relating to epidemics or pandemics such as COVID-19, including the impact of COVID-19 on the Company's business, financial condition, and results of operations. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. The Company does not assume any obligation to update or revise its forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by securities laws.

Click here to connect with Potent Ventures Inc. (CSE: POT) (FSE: 0OS) (OTCQB: POTVF) to receive an Investor Presentation.

Source

The Conversation (0)
Radiopharm Theranostics

Radiopharm Theranostics Targets Nasdaq Listing by End of 2024

Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, today announced it expects to obtain a secondary listing on the Nasdaq Capital Market by the end of 2024.

Keep reading...Show less
Row of test tubes and pipette with chemical droplet chemical coming from it.

Top 5 NASDAQ Biotech Stocks of 2024

The NASDAQ Biotechnology Index (INDEXNASDAQ:NBI) has traded at three-year highs in the first half of 2024 in response to looming interest rate cuts, breakthrough innovations and increased deals in the space.

After dropping to a low of 3,637.05 in October 2023, the index climbed to start 2024 at 4,457.02. It did hit a bump in the road early in Q2 when it plunged to 4,056.3 in April, but it quickly recovered and has since tracked even higher, reaching 4,634.21 on June 24. But while the current economic environment means the biotech sector may have a complex road ahead, robust growth could be in store in the future.

According to a recent report from Precedence Research, the global biotech market is expected to grow at a compound annual growth rate of 11.8 percent from now to 2033, reaching a valuation of US$4.25 trillion.

Keep reading...Show less
Radiopharm Theranostics

First Patient Dosed with PD-L1 Nanobody in Phase 1 Therapeutic Non-Small Cell Lung Cancer Trial

Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, is pleased to announce the therapeutic dosing of the first patient in its Phase 1 clinical trial of RAD 204, a proprietary nanobody which targets Programmed death-ligand 1 (PD-L1)-positive expression in Non-Small Cell Lung Cancer (NSCLC), the most common type of lung cancer.

Keep reading...Show less
Test tubes.

Can AI Help Detect Cancer? Data Analysis Could Open Up Possibilities for Healthcare Industry

Artificial intelligence (AI) has emerged as a valuable tool for solving complex societal issues, and although it's a new industry, its impact is already being felt in key areas of the life science sector.

AI models in healthcare are quickly advancing beyond basic tasks like medical transcription and administrative streamlining; many systems can now effectively analyze extensive genetic data.

By harnessing AI models' ability to identify patterns and make predictions, medical professionals can institute more effective, personalized treatments and develop precision tests to catch diseases earlier.

Keep reading...Show less
Biotech therapy capsule containing DNA strand surrounded by cells.

Top 3 Canadian Biotech Stocks of 2024

Biotech is a dynamic industry that is driving scientific advancements and innovation in healthcare.

According to Grandview Research, the global biotech market was worth US$1.55 trillion in 2023, and the firm expects it to grow at a CAGR of 13.96 percent between 2024 and 2030 to reach a value of US$3.08 trillion.

In Canada, the biotech industry is home to companies pursuing cutting-edge therapies and medical technologies, and the Investing News Network has identified the top three biotech stocks based on their year-on-year gains.

Keep reading...Show less
Radiopharm Theranostics

Investor Webinar – 3pm AEST Tuesday 2 July

Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, is pleased to announce that CEO and Managing Director Riccardo Canevari and Executive Chairman Paul Hopper will conduct an investor webinar to provide an update following announcement of the Company’s $70 million capital raising.

When: 3pm AEST, Tuesday 2 July 2024

Keep reading...Show less

Latest Press Releases

Related News

×